Citation Impact
Citing Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy
2009
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
2016
Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial
2014
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
2010
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Breast cancer
2016 Standout
Rheumatoid arthritis
2016 Standout
Cancer to bone: a fatal attraction
2011 Standout
Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
2012
Burden of liver diseases in the world
2018 Standout
Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
2012 Standout
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
The metabolic syndrome
2010 Standout
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Allostatic load biomarkers of chronic stress and impact on health and cognition
2009 Standout
Predicting the graft survival for heart–lung transplantation patients: An integrated data mining methodology
2009
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
2011
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
2010
The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis
2015
Risk scoring in the assessment of cardiovascular risk
2006
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Prolactinomas
2010
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
2012
Osteoporosis: now and the future
2011 Standout
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
2014
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
2009
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
2012
The Metabolic Syndrome and Cardiovascular Risk
2010 Standout
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review
2006
Type 2 diabetes
2017 Standout
Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
2012
A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance
2021 Standout
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5
2012
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
2017 Standout
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death
2007 Standout
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Hyperprolactinemia and Prolactinomas
2008
The metabolic syndrome—a new worldwide definition
2005 Standout
Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
2014
Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women
2006
Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4
2012
Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis
2016
Mining electronic health records: towards better research applications and clinical care
2012 Standout
Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review
2011
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Evaluating the cost‐effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK
2012
Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline
2006 Standout
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss
2005 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2018 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links.
2019
The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation
2009 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
2016
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Model Transparency and Validation
2012
Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update
2021
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis
2013
Model Parameter Estimation and Uncertainty Analysis
2012
Advances in the Treatment of Prolactinomas
2006
Dynamic Transmission Modeling
2012
Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit
2016
Modeling Using Discrete Event Simulation
2012
The Metabolic Syndrome
2008 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
Surgery for weight loss in adults
2014 Standout
General Cardiovascular Risk Profile for Use in Primary Care
2008 Standout
The Metabolic Syndrome: Time for a Critical Appraisal
2005 Standout
Decision Making in Health and Medicine: Integrating Evidence and Values
2001
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Works of Phil McEwan being referenced
Long‐term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
2005
Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom
2013
Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany
2012
Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control
2008
Evaluating the performance of the Framingham risk equations in a population with diabetes
2004
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
2012
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
2011
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
2014
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK
2015
Review of Utility Values for Economic Modeling in Type 2 Diabetes
2014
The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain
2009
Evaluation of the cost-effectiveness of Sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom
2005
Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013
2015
Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
2013
Validation of the IMS CORE Diabetes Model
2014
Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository
2004
Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes
2006
The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis
2007
Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK
2007
Conceptualizing a Model
2012
Long-Term Remission Following Withdrawal of Dopamine Agonist Therapy in Subjects With Microprolactinomas
2005